← All trials
NCT02025036
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2014
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 630
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Henan Medical UniversityLead sponsor
- Anyang Regional HospitalOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Luoyang Central HospitalCollaborator
- Nanyang Central HospitalCollaborator
- Sanmenxia Central HospitalCollaborator
- Anyang Regional HospitalCollaborator
- Henan Medical UniversityCollaborator
- Xinxiang Medical UniversityOverall official - principal investigator
- Xinyang Medical CollegeCollaborator
- People's Liberation Army of ChinaCollaborator
- People's Liberation Army of ChinaOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Henan Medical UniversityStudy director
- Henan Medical UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.